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ABSTRACT
Breast cancer (BC) in young women is rare, affecting only 4–6% of women under the age of 40. Regardless, BC remains the 
most common malignancy among younger patients. Recently, a significant increase in BC rates has been observed among 
pre-menopausal subjects. Breast cancer in young women requires special attention due to its specific morphologic and 
prognostic characteristics and unique aspects, including fertility preservation and psychosocial issues (e.g. its impact on 
family life and career). Young women are more likely to have tumors with higher incidence of negative clinicopathologic 
features (higher histological grade, more lymph node positivity, lower estrogen receptor (ER) positivity, higher rates of 
Her2/neu overexpression). Also, they tend to be diagnosed at more advanced stages of the disease. That, in turn, con-
tributes to less favorable prognosis as compared to older women. Young women are generally treated similarly to older 
patients. Surgical management includes mastectomy or breast-conserving surgery, followed by radiation therapy (younger 
women have higher local recurrence rates than older women, especially after breast-conserving therapy). Although the 
basics of chemotherapy are the same for patients of all ages, younger women have some special considerations. It is 
important to consider options for fertility preservation before starting systemic treatment. Patients should have access to 
genetic testing as their results may affect the choice of therapy. Younger women and their families should receive adequate 
psychological support and counselling. 
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INTRODUCTION
Attempts have been made to define ‘young age’ but the 
definitions are frequently ambiguous and open to interpreta-
tion. In case of breast cancer (BC), ‘young patients’ are women 
diagnosed with cancer before the age of 40, although such 
occurrence is rare as BC typically affects older women, over 
the age of 50. Identification of young patients is clinically valid 
as BC in that age group presents with certain biological differ-
ences and often requires special management. Typically, BC 
in young women has a more aggressive course, less favorable 
prognosis, and worse survival rates as compared to older sub-
jects [1]. Also, treatment of young patients is associated with 
numerous additional challenges, i.e. preservation of fertility, 
possibility of continuing the pregnancy despite the diagnosis, 
or problems with breast feeding. BC in young women is also 
a social issue since the disease often appears during the time 
of the highest family and career activity.
EPIDEMIOLOGY 
BC is the most common malignancy in women in Poland 
— in 2012 its incidence reached 17000 [2]. The risk increases 
with age but women between 50–69 years of age are the 
most frequently affected, and only 2–7% of all cases are 
diagnosed in the age group under 40 [3]. Despite the risk 
for BC in the third decade of life being only 0.04% per year, 
it remains the most common malignancy in women under 
35 years of age [4]. In Poland, a growing number of cases 
are registered every year. Even if morbidity rates in women 
under 40 years of age have not been statistically significantly 
different since the 70s of the previous century, (e.g. in the 
United States), due to a steadily increasing number of cases 
in that age group, the absolute number of young women 
with BC continues to grow [5]. Some sources also report 
increased BC incidence in young women. The GRELL study 
analyzed epidemiological data from 7 European countries 
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and found the mean rate to be increasing by 1.2% annually 
between 1990-2008. The rate was the highest in the age 
group between 15–34 years as compared to older women 
(34–39 years of age), especially in France and Portugal [6]. 
The fact that a growing number of patients are diagnosed in 
more advanced stages, which is the direct consequence of 
lack of screening and preventive measures in that age group 
and more aggressive disease course in young women, has 
become a cause for concern. Delayed diagnosis may also 
result from lack of oncological vigilance among practitioners 
who encounter young women with breast changes (during 
pregnancy, puerperium or lactation).
BC incidence varies greatly, depending on race and 
ethnicity, which is especially visible in a multi-ethnic Ameri-
can society. In the age group of > 45 years, the disease is 
more frequently detected in Caucasian women as compared 
to African-Americans, whereas in the age group of ≤ 35 years 
the morbidity and mortality rates in the latter group are 
2- and 3-fold higher, respectively as compared to the former 
[5, 7]. Also, genetic background and family history are more 
often detected in women under 40.
DIAGNOSTIC TESTING
Young women with suspicion of BC ought to be diag-
nosed by an experienced team of doctors and even despite 
relatively low risk for BC in patients < 40 each abnormality 
detected on palpation requires speedy and careful diag-
nostic testing using the approach known as the ‘triple test’ 
— physical breast examination, imaging test, and cyto- or 
histopathologic verification. It allows to confirm the initial 
diagnosis in 95% of the cases and avoid surgical removal of 
benign lesions. The use of oral contraceptives has no effect 
on the possibility of performing the imaging test. Ultrasound 
tests may be performed at any phase of the menstrual cycle, 
mammogram in the first two weeks and MRI in the second 
week of the menstrual cycle, although in case of a dynamic 
pattern of the lesions it is vital to conduct the tests as soon 
as possible [4, 8]. The literature offers no data on the ben-
efits of regular preventive screening in women < 40 [9], 
as dense structure of the breasts in that age group often 
hinders proper interpretation of mammogram results. Due 
to low specificity of mammogram imaging in young women, 
its application in screening programs might increase the 
number of false-positive results and become the source of 
unnecessary stress and anxiety. 
Although the use of breast implants has no correlation 
with the risk for BC, their presence lowers the effective-
ness of mammogram testing, thus contributing to delayed 
diagnosis [10, 11]. Therefore, women who consider breast 
implants ought to be informed about that risk.
The most valuable imaging techniques in young wom-
en include ultrasound and MRI, although they both have 
their limitations and are not recommended for screening in 
women < 40. Ultrasound is a valuable screening tool, com-
plementary to a mammogram in case of significant density 
of the breast, but the sensitivity of the test itself is low and its 
value depends largely on the skills and expertise of the so-
nographer. In turn, MRI has high sensitivity but its insufficient 
specificity results in a significant number of false-positive find-
ings. Regardless, the method is currently being considered 
as a screening tool for young women at high risk for BC [4]. 
Perhaps medical advances will soon propagate new imaging 
techniques, e.g. contrast-enhanced mammogram, ultrasound 
elastography, or MRI spectroscopy. 
The test itself is the cheapest and the most available 
diagnostic method. Young women should be advised to 
perform breast self-exam and undergo breast exam during 
the doctor’s appointment on regular basis, even if clini-
cal data on the correlation between such management 
and survival are limited. Regardless, these methods detect 
one-third of BC malignancies in the entire population, with 
80% in women < 35 years of age who undergo no screening 
tests (mean tumor size is 2 cm) [12].
TUMOR BIOLOGY
Unfavorable prognostic factors are more often observed 
in young women as compared to their older peers. At dia- 
gnosis, the lesions are larger, less mature, less often con-
tain estrogen receptors (ER) and progesterone receptors 
(PR), with more cases of HER2 overexpression and vascular 
invasion [1]. Anders et al., in their retrospective study of 
700 tumors, found a higher rate of grade 3 tumors and lower 
number of lesions with expression of estrogen receptor in 
women < 45 years of age [13].
A retrospective observational study, which included 
histopathological characteristics of breast cancer in women 
< 40, has recently been published. In that large group of cases 
(2956) invasive ductal carcinomas were dominant — 86.5%, 
including 58.9% G3 tumors. Approximately 50% of the af-
fected women were diagnosed with metastases to axillary 
lymph nodes, and 27% had multifocal lesions. HER2 overex-
pression was observed in 24% of the tumors and estrogen 
receptors were found in 66% of the cases. Triple-negative 
(lack of ER, PR expression, and HER2 overexpression) tumors 
were detected in 19.9% of the patients [14]. In another 
study, triple-negative cancers were found in 26% of the af-
fected women and HER2 overexpression in 34% of women 
aged ≤ 40 [15]. A recent molecular classification of breast 
cancers, based on DNA-microarray analysis, distinguishes 
between 5 subtypes: luminal A, luminal B, HER2 overexpres-
sion, basal-like, and normal-like subtype with expression of 
genes typical for normal breast cells [16].
Molecular studies have confirmed that BC subtypes with 
worse prognosis are more often found in young women. 
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One study found basal cancers with the worst prognosis 
(typically, with the phenotype of triple-negative cancers) 
in 34% of young patients, with only 17% in older women. 
Luminal A cancer, with better prognosis, was detected in 
35% of the older and 17% of the younger women [17]. 
However, it seems that worse tumor biology in patients with 
BC is not only connected with less beneficial distribution 
of particular molecular subtypes of cancer. Analysis of the 
expression of various genes revealed that increased gene 
expression connected with poor prognosis is often found 
in young women [13]. 
Recently introduced genetic tests (Oncotype DX, Mam-
maPrint) are useful for the evaluation of the risk for recur-
rence in patients with early-stage disease, without metasta-
ses to the lymph nodes, with tumor showing ER expression 
and without HER2 overexpression. Such criteria are most 
often met by postmenopausal women and so the tests 
are commonly performed in older patients. Reports about 
young patients, rare as they are, have revealed high risk 
indices in that age group more often than in older women. 
The risk for disease recurrence was 56% and 82% (52/63) in 
the Oncotype DX, and MammaPrint tests, respectively [18]. 
SURGICAL MANAGEMENT
The rules of surgical management in young and older 
women are essentially the same. Radical breast amputa-
tion or conservative, breast-conserving management fol-
lowed by radiotherapy remain the standard approach in 
early-stage breast cancer, regardless of patient age [19]. 
Despite the fact that conservative treatment is associated 
with higher rate of local recurrence, both methods allow to 
achieve comparable survival rate [20]. Young age is an inde-
pendent risk factor for local recurrence after conservative 
management (patients aged < 35 are at a 9-fold higher risk 
than older women), but the OS remains unaffected [21]. Due 
to the specific expectations of that particular age group (the 
need to preserve sexuality, cosmetic result), conservative 
treatment ought to be offered to young patients as the first 
choice. Skin- and/or nipple-sparing mastectomy with imme-
diate reconstruction also meets patient expectations [22]. 
There are no special recommendations for young women 
as far as surgical management of the axillary lymph nodes 
is concerned. 
Prophylactic bilateral mastectomy remains the topic of 
much heated debate and considerable controversy. There 
is no evidence that such management benefits young 
non-carriers of the BRCA1 gene mutation diagnosed with 
breast cancer. Such approach may be taken into considera-
tion if the affected woman is determined to proceed, after 
providing detailed information about the risk for complica-
tions and enough time to avoid hasty decisions, fear, and 
anxiety. 
 ADJUVANT RADIOTHERAPY
Recommendations for adjuvant therapy are the same 
as in older women. Radiotherapy is always used after 
breast-conserving surgery, after mastectomy in case of 
large tumors (≥ 5 cm), or metastases to at least 4 lymph 
nodes. According to recommendations, radiotherapy is also 
advised in case of metastases to 1–3 lymph nodes in BC 
patients with unfavorable phenotype [24]. It is important to 
bear in mind that young women are at higher risk for local 
recurrence not only after breast-conserving surgery but also 
after mastectomy, so they benefit more from radiotherapy 
than their older peers [23, 24]. 
SYSTEMIC THERAPY
Chemotherapy
In Europe, adjuvant therapy is carried out in accordance 
with the regularly held bi-annual St. Gallen Conference 
(hence the St. Gallen Consensus). Earlier recommendations 
considered young age to be an independent, unfavora-
ble prognostic factor so all patients < 35 years of age re-
ceived adjuvant chemotherapy. According to the 2013 and 
2015 recommendations, patient age is no longer the deci-
sive factor for adjuvant chemotherapy. Tumor biology has 
a decisive influence and young patients receive the same 
kind of therapy as their older peers. Adjuvant chemotherapy 
is recommended in the following cases: 
 Ū cancers with the so-called triple-negative tumor phe-
notype (without ER and PR expression and without 
HER2 overexpression);
 Ū cancers with HER2 overexpression — recommendations 
include chemotherapy with anthracyclines and taxanes, 
plus annual therapy with trastuzumab, a monoclonal 
antibody against HER2;
 Ū cancers with ER expression (the so-called luminal can-
cers, treated predominantly with HT) — chemotherapy 
is used in case of additional risk factors which include 
high-grade (G3) tumors, metastases to at least 4 lymph 
nodes, high Ki-67 proliferation index, low steroid recep-
tor expression, and extensive infiltration of lymph and 
blood vessels [23]. 
Treatment of extensive disease in young patients re-
sembles therapy in older women. Young age should not be 
an indication for more aggressive forms of treatment [24]. 
Hormonal therapy
Hormonal therapy (HT) has a strong position in both, 
adjuvant treatment of early-stage BC and palliative therapy 
of the extensive disease in young women with BC which 
shows steroid receptor expression. However, it is not recom-
mended for neoadjuvant therapy in young women due to 
lack of evidence for its benefits. Tamoxifen, possibly with 
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ovarian function suppression (OFS), remains the gold stand-
ard in hormonal therapy. For many years, researchers have 
believed the 5-year period to be optimal for tamoxifen use. 
The ATLAS study revealed that a 10-year period lowers the 
mortality rate by one-third during the first 10 years since the 
initial diagnosis and by half in later years. However, at the 
same time, the study found an approximately 2-fold higher 
risk for cervical cancer in the group of patients receiving 
tamoxifen for 10 years [25]. Similar results were reported 
by the ATOM study. At present, prolonged adjuvant therapy 
with tamoxifen is believed to be possible in selected patients 
(both, pre- and postmenopausal) after careful analysis of 
their prognostic factors, the risk for late recurrence, esti-
mated disease-free survival, and possible complications. In 
hormone-dependent cancers, late recurrence after primary 
radical treatment poses a serious problem as the survival 
curves practically never reach a plateau, and the annual risk 
for recurrence, even after several years, is 2–3%. 
For a long time, there has been no proof for any benefits 
of using adjuvant therapy with aromatase inhibitors in pre-
menopausal patients. Two large randomized studies — SOFT 
and TEXT — compared exemestane with OFS versus tamox-
ifen, also with hormonal suppression. After an over 5-year 
observation, aromatase inhibitors combined with suppres-
sion were found to slightly although significantly (4% of 
relative difference) prolong median disease-free survival, 
although median overall survival (OS) was unaffected [26].
The SOFT study was designed to determine the role of 
ovarian suppression as well. In this three-arm study (tamoxi- 
fen vs. tamoxifen with ovarian suppression vs exemestane 
with OFS), combination therapy lowered the risk for disease 
recurrence in high-risk patients (after previous chemothera-
py), especially > 35 years of age, as compared to tamoxifen. 
The benefit was even greater in case of exemestane with OFS 
than tamoxifen with OFS [27]. Regardless, it is important to 
bear in mind that combination therapy is associated with 
a number of adverse symptoms due to premature meno-
pause, which significantly negatively impacts the quality of 
life of the young women.
In case of palliative treatment in young women, HT 
ought to be considered in all patients who do not require 
an aggressive course of action due to intensified clinical 
symptoms. In practice, HT in young women is typically used 
after patients achieved maximum response to chemother-
apy but the literature offers no reliable data on methods 
of combining different forms of HT with chemotherapy or 
biological therapy in that age group. 
Management in BRCA carriers
The risk for breast cancer in the carriers of the BRCA1 or 
BRCA2 gene mutation has been estimated at even 70% [28]. 
Healthy carriers ought to undergo screening tests, which 
allow for early BC detection. They should perform breast 
self-exam every month since the age of 18, and report for 
physical evaluation since the age of 25. Noteworthy, ul-
trasound test in that age group is characterized by high 
specificity but relatively low sensitivity, whereas regular 
mammogram at such young age remains the source of much 
controversy due to cyclic exposure to ionizing radiation, so 
MRI is an especially useful tool in that population.
Local disease recurrence or cancer spread to the other 
breast are significantly more often found in BRCA carriers 
patients than in women with sporadic BC.
The risk for local recurrence is obviously greater if con-
servative treatment rather than radical management was 
applied, although type of surgery in the latter approach 
has no correlation with the overall survival [29]. Current 
data indicate that radiation as an element of conservative 
management does not elevate the risk for carcinogenesis 
in BRCA carriers as compared to other BC patients. The 
risk for cancer in the other breast among BRCA carriers 
has been estimated at 3–4% annually. Therefore, preven-
tive mastectomy of the other breast should be offered to 
these patients as such management greatly improves the 
OS [30]. Nipple-areola complex sparing mastectomy allows 
to maintain oncologic safety and achieve good effects after 
the subsequent reconstructive surgery.
Systemic adjuvant therapy in BRCA carriers is consist-
ent with the general recommendations. Although BRCA 
gene damage seems to be a predictive factor for disease 
sensitivity to drugs which damage DNA strands (cisplatin, 
carboplatin), we lack conclusive evidence to recommend 
other protocols of adjuvant therapy [23]. Platinum deriva-
tives are sometimes used in advanced disease. 
FERTILITY PRESERVATION AND MATERNITY 
AFTER CANCER THERAPY
Patients < 40 years of age are in fact women in the 
reproductive age. Recent years have revealed a steady 
trend for delayed motherhood so doctors will continue to 
treat women with diagnosed breast cancer who are either 
nulliparous or wish to have more children. Thus, fertility 
preservation has become an important aspect of breast 
cancer therapy. Chemotherapy is administered to the ma-
jority of young cancer patients, which may damage the 
ovaries. The extent of the damage depends predominantly 
on patient age, type and dose of the drug. Observational 
studies reported cessation of menstruation after standard 
chemotherapy in about 25% of BC patients < 30 years of 
age, 30–70% aged 30–40 years, and 80% aged > 40 [31]. 
However, post-therapy amenorrhea does not unequivo-
cally signify infertility, while menstruation does not equal 
the procreative potential. As for the evaluation of fertility, 
measurement of the anti-Müllerian hormone (AMH) is a use-
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ful indicator of the ovarian reserve. Therefore, AMH levels 
should be checked not only after treatment completion 
but also before therapy. Estradiol, FSH, or inhibin levels will 
not give conclusive results as far as fertility is concerned. 
HT also affects fertility and although toxicity of tamoxifen 
is infinitely smaller than chemotherapy, duration of the 
treatment presents a problem. Until recently, a 5-year ta-
moxifen therapy was the standard management but after 
the results of ATLAS and ATOM studies have been pub-
lished, a 10-year-long treatment has been recommended 
for patients from high-risk groups. The latest St. Gallen 
recommendations allow for a break in the adjuvant HT to 
conceive and treatment recommencement after delivery. 
During chemotherapy, gonadoliberin analogues may be 
used in patients with ER-negative cancers to preserve fertil-
ity. However, those medicines have not been approved in 
such indications and their effectiveness is limited.
Pregnancy after breast cancer treatment does not in-
crease the risk for disease recurrence and for congenital 
fetal malformations. Also, the newborns may be breastfed. 
PROGNOSIS
Breast cancer in young women presents a number of 
different biological features, resulting in shorter progres-
sion-free and overall survival as compared to other age 
groups. Therefore, the St. Gallen Expert Panel (2005) found 
age to be an unfavorable prognostic factor. The experts 
stated that young patients are never actually in the low-risk 
group and, as such, should always undergo systemic treat-
ment. Currently, it is believed that the decision about sys-
temic treatment of young women should be based — as in 
other age groups — on the evaluation of the biological fea-
tures of the tumor, tumor stage, and concomitant diseases. 
Palliative care of young women with BC presents a par-
ticular challenge as these patients are usually young moth-
ers and the whole family requires complex care. 
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